← ETFs
Start this SIP →
Nippon India Mutual Fund · ETFs
Nippon India Nifty Pharma ETF
The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Benchmark · NIFTY Pharma TRITER · 0.21%Inception · 05-07-2021
NAV
₹25.18
+2.67% · as of 14-05-2026
Since inception
12.18%
CAGR
Benchmark (inception)
14.44%
CAGR
Fund size
₹14 Cr
AUM
Expense ratio
0.21%
30-04-2026
Performance
Returns vs benchmark & category
Since inception: +12.18% CAGR vs benchmark +14.44%.
Portfolio
Where the money is invested
Top holdings
SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/-22.91%
Dr. Reddys Laboratories Ltd9.41%
DIVIS LABORATORIES LIMITED EQ NEW RS. 2/-9.32%
CIPLA LIMITED EQ NEW FV RS.2/-8.49%
LUPIN LIMITED EQ NEW F.V. RS.2/-6.91%
TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/-5.43%
LAURUS LABS LIMITED EQ NEW FV RS. 2/-4.76%
AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/-4.49%
GLENMARK PHARMACEUTICALS LIMITED EQ NEW FV RE.1/-3.96%
ALKEM LABORATORIES LIMITED EQ3.80%
Sector allocation
Healthcare99.97%
Riskometer
LowVery High
Very High
What if you'd SIP'd here?
@ 12.2% p.a.₹10,000
10 years
Projected value
₹23,48,453
Invested: ₹12,00,000
Gained: ₹11,48,453
Illustration based on fund's since-inception return. Past performance is not indicative of future returns.
Risk Analysis
How this fund manages risk
Fund manager
J
Jitendra Tolani
Manager since fund inception data not available
ISIN & identifiers
AMFI code
149008
ISIN (Growth)
INF204KC1089
ISIN (Div Re-inv)
—
Status
Open Ended Schemes
Peers
Other ETFs funds
Want a personalised recommendation?
Our team will tell you whether this fund fits your goals, allocation and risk profile — and suggest peers if it doesn't.